Therapy Areas: Central Nervous System
Lundbeck launches clinical trial for CD40L blocker Lu AG22515
3 October 2024 - Pharmaceutical company H. Lundbeck A/S (CPH:HLUN) announced on Thursday the initiation of a clinical trial for its CD40L blocker, Lu AG22515, targeting Thyroid Eye Disease, an autoimm...
Charles River and Lundbeck partner to advance neurological drug discovery using AI-powered Logica
2 October 2024 - Charles River Laboratories International Inc (NYSE: CRL), a provider of products, models, services and guidance for biomedical research and drug development, on Wednesday announced an...
Vesper Bio announces positive Phase I results for FTD treatment
4 September 2024 - Danish clinical stage biotech Vesper Bio ApS announced on Wednesday that it has successfully completed a Phase I study for its lead candidate, VES001, a potential disease-modifying ...
Telix Pharmaceuticals submits TLX101-CDx NDA to US FDA
28 August 2024 - Telix Pharmaceuticals Limited (ASX: TLX), an Australia-based biopharmaceutical company, announced on Wednesday that it has submitted a New Drug Application (NDA) to the United States ...
Argent BioPharma partners with SINTEF to advance chronic wound management
21 August 2024 - Drug discovery company Argent BioPharma (ASX: RGT) (LSE: RGT) (OTCQB: RGTLF) on Monday announced a strategic collaboration with SINTEF, a large European independent research organisat...
NRx Pharmaceuticals and HOPE Therapeutics align with FDA on Pediatric Study Plan for NRX-100
29 July 2024 - NRx Pharmaceuticals Inc (Nasdaq: NRXP) announced on Monday that with HOPE Therapeutics Inc, it has secured alignment with the US Food and Drug Administration (FDA) on the initial Pediat...